CD38 and neoplasm: Daratumumab-induced on-tumor activity occurs through several CD38 immune-mediated actions (complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis), apoptosis, and modulation of CD38 enzymatic activity [3–6].